Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Extracellular Vesicles as Biomarkers of Diseases
share announcement

Extracellular Vesicles as Biomarkers of Diseases

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 6708

Special Issue Editors

Dr. Mebarek Saida

E-Mail Website
Guest Editor
University Lyon, Université. Claude Bernard Lyon 1, CNRS UMR 5246, ICBMS, F-69622 Lyon, France
Interests: lipid signaling and signal transduction; prostate cancer; bone metastasis; vascular calcification; atherosclerosis; extracellular vesicles
Special Issues, Collections and Topics in MDPI journals
Dr. Leyre Brizuela

E-Mail Website
Guest Editor
University Lyon, Université. Claude Bernard Lyon 1, CNRS UMR 5246, ICBMS, F-69622 Lyon, France
Interests: lipid signaling and signal transduction; prostate cancer; bone metastasis; vascular calcification; atherosclerosis; extracellular vesicles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This issue aims at summarizing the most recent literature on extracellular vesicles (EVs) as disease biomarkers, as well as candidates for cell-free therapeutic approaches.

EVs (a terminology that encompasses microparticles, exosomes, and apoptotic bodies among others) are active players of cell-to-cell communication and convey fundamental information between cells. These microstructures contain proteins, lipids, and genetic information able to modify the phenotype and function of the target cells. EVs carry specific markers of the cell of origin, which could reveal the state of the cell and could be used to diagnose diseases. Indeed, EVs have attracted considerable interest in the metabolic diseases such as obesity or diabetes, in cardiovascular diseases field as reservoirs of molecules produced during arterial remodelling, in the pathogenesis of neuro-degenerative diseases such as Parkinson and Alzheimer’s diseases, but also in the cancer domain. In this Special Issue, we would like to receive experimental and clinical articles or reviews about how EVs can be identified as biomarkers of diseases.

Dr. Mebarek Saida
Dr. Leyre Brizuela
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extracellular vesicles
  • metabolic syndrome
  • cancer
  • cardiovascular diseases
  • neurodegenerative diseases
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 8343 KiB  
Article
EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC
by Hai-Ming Liu, Zi-Li Yu, Hou-Fu Xia, Lin-Zhou Zhang, Qiu-Yun Fu, Yi Wang, Hong-Yun Gong and Gang Chen
Biomolecules 2024, 14(7), 820; https://doi.org/10.3390/biom14070820 - 9 Jul 2024
Viewed by 630
Abstract
In Asian populations with non-small-cell lung cancer (NSCLC), EGFR mutations are highly prevalent, occurring in roughly half of these patients. Studies have revealed that individuals with EGFR mutation typically fare worse with immunotherapy. In patients who received EGFR tyrosine kinase inhibitor (TKI) treatment [...] Read more.
In Asian populations with non-small-cell lung cancer (NSCLC), EGFR mutations are highly prevalent, occurring in roughly half of these patients. Studies have revealed that individuals with EGFR mutation typically fare worse with immunotherapy. In patients who received EGFR tyrosine kinase inhibitor (TKI) treatment followed by anti-PD-1 therapy, poor results were observed. The underlying mechanism remains unclear. We used high-resolution flow cytometry and ELISA to detect the circulating level of small extracellular vesicle (sEV) PD-L1 in NSCLC individuals with EGFR mutations before and after receiving TKIs. The secretion amount of sEV PD-L1 of lung cancer cell lines with EGFR mutations under TKI treatment or not were detected using high-resolution flow cytometry and Western blotting. The results revealed that patients harboring EGFR mutations exhibit increased levels of sEV PD-L1 in circulation, which inversely correlated with the presence of CD8+ T cells in tumor tissues. Furthermore, tumor cells carrying EGFR mutations secrete a higher quantity of PD-L1-positive sEVs. TKI treatment appeared to amplify the levels of PD-L1-positive sEVs in the bloodstream. Mutation-induced and TKI-induced sEVs substantially impaired the functionality of CD8+ T cells. Importantly, our findings indicated that EGFR mutations and TKI therapies promote secretion of PD-L1-positive sEVs via distinct molecular mechanisms, namely the HRS and ALIX pathways, respectively. In conclusion, the increased secretion of PD-L1-positive sEVs, prompted by genetic alterations and TKI administration, may contribute to the limited efficacy of immunotherapy observed in EGFR-mutant patients and patients who have received TKI treatment. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Biomarkers of Diseases)
►▼ Show Figures

Figure 1

14 pages, 1609 KiB  
Article
Circulating Small Extracellular Vesicles Reflect the Severity of Myocardial Damage in STEMI Patients
by Marta Zarà, Andrea Baggiano, Patrizia Amadio, Jeness Campodonico, Sebastiano Gili, Andrea Annoni, Gianluca De Dona, Maria Ludovica Carerj, Francesco Cilia, Alberto Formenti, Laura Fusini, Cristina Banfi, Paola Gripari, Calogero Claudio Tedesco, Maria Elisabetta Mancini, Mattia Chiesa, Riccardo Maragna, Francesca Marchetti, Marco Penso, Luigi Tassetti, Alessandra Volpe, Alice Bonomi, Giancarlo Marenzi, Gianluca Pontone and Silvia Stella Barbieriadd Show full author list remove Hide full author list
Biomolecules 2023, 13(10), 1470; https://doi.org/10.3390/biom13101470 - 29 Sep 2023
Cited by 2 | Viewed by 1312
Abstract
Circulating small extracellular vesicles (sEVs) contribute to inflammation, coagulation and vascular injury, and have great potential as diagnostic markers of disease. The ability of sEVs to reflect myocardial damage assessed by Cardiac Magnetic Resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) is unknown. [...] Read more.
Circulating small extracellular vesicles (sEVs) contribute to inflammation, coagulation and vascular injury, and have great potential as diagnostic markers of disease. The ability of sEVs to reflect myocardial damage assessed by Cardiac Magnetic Resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) is unknown. To fill this gap, plasma sEVs were isolated from 42 STEMI patients treated by primary percutaneous coronary intervention (pPCI) and evaluated by CMR between days 3 and 6. Nanoparticle tracking analysis showed that sEVs were greater in patients with anterior STEMI (p = 0.0001), with the culprit lesion located in LAD (p = 0.045), and in those who underwent late revascularization (p = 0.038). A smaller sEV size was observed in patients with a low myocardial salvage index (MSI, p = 0.014). Patients with microvascular obstruction (MVO) had smaller sEVs (p < 0.002) and lower expression of the platelet marker CD41–CD61 (p = 0.039). sEV size and CD41–CD61 expression were independent predictors of MVO/MSI (OR [95% CI]: 0.93 [0.87–0.98] and 0.04 [0–0.61], respectively). In conclusion, we provide evidence that the CD41–CD61 expression in sEVs reflects the CMR-assessed ischemic damage after STEMI. This finding paves the way for the development of a new strategy for the timely identification of high-risk patients and their treatment optimization. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Biomarkers of Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 2141 KiB  
Review
Emerging Roles of Extracelluar Vesicles Derived from Bacteria, Mammalian or Plant Cells in the Pathogenesis and Clinical Application of Neurodegenerative Diseases
by Yihong Li, Chenglong Zhou, Huina Liu, Ting Cai and Huadong Fan
Biomolecules 2024, 14(3), 312; https://doi.org/10.3390/biom14030312 - 6 Mar 2024
Viewed by 1799
Abstract
A growing number of studies have indicated that extracellular vesicles (EVs), such as exosomes, are involved in the development of neurodegenerative diseases. Components of EVs with biological effects like proteins, nucleic acids, or other molecules can be delivered to recipient cells to mediate [...] Read more.
A growing number of studies have indicated that extracellular vesicles (EVs), such as exosomes, are involved in the development of neurodegenerative diseases. Components of EVs with biological effects like proteins, nucleic acids, or other molecules can be delivered to recipient cells to mediate physio-/pathological processes. For instance, some aggregate-prone proteins, such as β-amyloid and α-synuclein, had been found to propagate through exosomes. Therefore, either an increase of detrimental molecules or a decrease of beneficial molecules enwrapped in EVs may fully or partly indicate disease progression. Numerous studies have demonstrated that dysbiosis of the gut microbiota and neurodegeneration are tightly correlated, well-known as the “gut–brain axis”. Accumulating evidence has revealed that the gut bacteria-derived EVs play a pivotal role in mediating microbe–host interactions and affect the function of the “gut–brain axis”, which subsequently contributes to the pathogenesis of neurodegenerative diseases. In this review, we first briefly discuss the role of EVs from mammalian cells and microbes in mediating the progression of neurodegenerative diseases, and then propose a novel strategy that employs EVs of plants (plant cell-derived exosome-like nanoparticles) for treating neurodegeneration. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Biomarkers of Diseases)
►▼ Show Figures

Graphical abstract

20 pages, 2745 KiB  
Review
Do Media Extracellular Vesicles and Extracellular Vesicles Bound to the Extracellular Matrix Represent Distinct Types of Vesicles?
by Saida Mebarek, Rene Buchet, Slawomir Pikula, Agnieszka Strzelecka-Kiliszek, Leyre Brizuela, Giada Corti, Federica Collacchi, Genevieve Anghieri, Andrea Magrini, Pietro Ciancaglini, Jose Luis Millan, Owen Davies and Massimo Bottini
Biomolecules 2024, 14(1), 42; https://doi.org/10.3390/biom14010042 - 28 Dec 2023
Cited by 1 | Viewed by 2127
Abstract
Mineralization-competent cells, including hypertrophic chondrocytes, mature osteoblasts, and osteogenic-differentiated smooth muscle cells secrete media extracellular vesicles (media vesicles) and extracellular vesicles bound to the extracellular matrix (matrix vesicles). Media vesicles are purified directly from the extracellular medium. On the other hand, matrix vesicles [...] Read more.
Mineralization-competent cells, including hypertrophic chondrocytes, mature osteoblasts, and osteogenic-differentiated smooth muscle cells secrete media extracellular vesicles (media vesicles) and extracellular vesicles bound to the extracellular matrix (matrix vesicles). Media vesicles are purified directly from the extracellular medium. On the other hand, matrix vesicles are purified after discarding the extracellular medium and subjecting the cells embedded in the extracellular matrix or bone or cartilage tissues to an enzymatic treatment. Several pieces of experimental evidence indicated that matrix vesicles and media vesicles isolated from the same types of mineralizing cells have distinct lipid and protein composition as well as functions. These findings support the view that matrix vesicles and media vesicles released by mineralizing cells have different functions in mineralized tissues due to their location, which is anchored to the extracellular matrix versus free-floating. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Biomarkers of Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop